SAN DIEGO--(BUSINESS WIRE)--April 29, 2004--Pharmessen Scientific, Inc. (Other OTC: PASC.PK), a nutraceutical and pharmaceutical research company focused on providing leading supplements and medications for better general health, announces today that it has received its first international purchase order and deposit for the company’s SLIMTRAX(TM) products. This order, valued at more than $55,000, is part of an estimated one year, $500,000 distribution agreement between Pharmessen and EuroVloot e.KFM, a nutraceutical distributor based in Gyhum, Germany. SLIMTRAX(TM) is a proprietary blend of herbal essential oils scientifically designed to reduce hunger. As a pure, herbal, weight-management supplement, SLIMTRAX(TM) is entirely free of ephedrine and caffeine.
Mr. George Macleod, Pharmessen’s Chief Executive Officer commented, “We are excited to expand our product recognition into international markets.” Management believes that this relationship will become a catalyst for other international relationships. “This sale is an important step in the overall growth of the company, particularly in the expansion of sales outside of the United States, which represent significant market opportunities for our products.”
Pharmessen was founded in 2001 by its President & CEO Dr. Dusan G. Ninkov, DVM, MST and PHD Pharmacology. Dr. Ninkov is the holder of two United States patents. In addition to SLIMTRAX(TM), Pharmessen’s scientific team continues to focus on the production of novel supplements and medications, including MAXOPLEX(TM), a powerful combination of herbal oils acting as an extremely effective anti-oxidant and GOLFOFLEX(TM), a water activated pure herbal anti-oxidant food supplement.
Mr. Macleod is also proud to announce Dr. Ninkov’s appointment to Chief Scientific Officer of the company. According to Mr. Macleod, “This position is of great significance and one that further illustrates Pharmessen’s commitment to the research and development of new and complementary products.”
About Pharmessen Scientific, Inc.
Pharmessen, Inc. is a nutraceutical and pharmaceutical company focused on research, development, production and marketing of natural food supplements and pharmaceutical compounds. Pharmessen’s goal is to provide customers with superb products containing active ingredients extracted from organically grown plants provided by reputable suppliers around the globe. Pharmessen’s scientific team is presently focused on developing new anti-microbial agents in order to improve the treatments of diseases caused by multi-resistant pathogens, on producing excellent dietary supplements to help athletes improve their performance, and on providing general population interested in healthy life style with natural products of extraordinary quality.
Additional information can be found on our website: www.pharmessen.com or by calling:
Investor Relations MacReport.Net, Inc. Mr. Tom Speciale 631-393-5075 www.macreport.net
Safe Harbor Statement
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; Triangle Multi-Media’s ability to execute its business model and strategic plans; and the risks described from time to time in the company’s Securities and Exchange Commission filings.
Contacts
MacReport.Net, Inc.
Investor Relations Mr. Tom Speciale, 631-393-5075 www.macreport.net